1. Scrip
  2. >>Focus On Asia
  3. >>China

43 Pharmas Apply To Make Generics Of Off-Patent Plavix In China

China’s State FDA received applications from 43 Chinese drug companies to manufacture generics of Sanofi’s $10-billion anti-clotting drug Plavix, whose patent expired in May.

China’s State FDA received applications from 43 Chinese drug companies to manufacture generics of Sanofi’s $10-billion anti-clotting drugPlavix (clopidogrel), whose patent expired in May. Fifteen companies have gained approvals, including nine API makers (including Shenzhen Salubris Pharmaceutical Co., Ltd.) and two formulation producers (including Henan XInShuaike Pharmaceutical Co., Ltd.). According to SFDA figures, Plavix sales growth subdued from 65.7% in 2007 to 22% in 2011, and sales will likely reach RMB 20 billion in 2015, from RMB 6.8 billion in 2010. Looking forward, the drug will face competition from the increasingly prominent Taijia (clopidogrel) manufactured by Shenzhen Salubris, whose market share grew from 9.2% to 26.69% during 2006-2011, and other upcoming generics. (Click Here For More - Chinese Language

)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 
• By Andrew McConaghie

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

BlissBio Goes Solo On HER2-Targeting ADC After Eisai Exit

 
• By Dexter Jie Yan

BlissBio is to single-handedly move BB-1701, its eribulin-containing, HER2-targeting antibody-drug conjugate, into a global pivotal Phase II/III program for HER2-expressing, Enhertu-resistant breast cancer.

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

More from Focus On Asia

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 
• By Anju Ghangurde

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By Lisa Takagi

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.